Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Toyonaka, Osaka, Japan. masahide.oodan@shionogi.co.jp
Abstract:
Our lead compound 1 showed high affinity for both CB1 and CB2 receptors, suggesting the possibility of inducing psychoactive side effects through the CB1 receptor in the brain. To solve this issue, polar functional groups were introduced at the 3-position of the pyridone core of compound 1 to find CB1/2 dual agonists such as 17 and 20 which did not show any CNS side effects.